BioNTech is acquiring a preclinical T cell receptor program (TCR) from Medigene, as well as licenses to the biotech’s TCR technologies. The agreement helps BioNTech expand its scope in cancer immunotherapy with a new approach for addressing solid tumors.
One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies' potential outside of the blood cancer space.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
The company's product is a T-cell receptor therapy, or TCR. While TCRs have been restricted by genotype, Pact says it has engineered its cells to overcome that restriction.
The company, part of Gilead Sciences since 2017, had placed an early emphasis on ensuring manufacturing capacity could meet demand - a key consideration in cell and gene therapy.